论文部分内容阅读
为了研究蛋白酶体抑制剂硼替佐米对急性白血病K562细胞株核因子κB(NF-κB)及细胞间黏附分子(ICAM-1)表达的影响,用含10%小牛血清的RPMI1640培养液体外培养K562细胞,用0、10、20、30、50、100nmol/L的硼替佐米干预K562细胞6小时后收集细胞。用SP免疫组织化学法测各组细胞NF-κB活性,并以反转录聚合酶链反应(RT-PCR)分析K562细胞ICAM-1表达的变化。结果表明:各药物处理组K562细胞NF-κB的活性和ICAM-1的表达均明显受抑制,与对照组相比,存在显著性差异(p<0.05),且各组NF-κB活性与ICAM-1表达成正相关。结论:蛋白酶体抑制剂硼替佐米可能通过抑制NF-κB活性下调细胞间黏附分子ICAM-1的表达,这为白血病靶向治疗提供了一个新的途径。
In order to investigate the effect of proteasome inhibitor bortezomib on the expression of NF-κB and ICAM-1 in acute leukemia K562 cells, RPMI1640 medium containing 10% calf serum was used to culture in vitro K562 cells, K562 cells were treated with 0, 10, 20, 30, 50, 100 nmol / L bortezomib 6 hours after the cells were harvested. The expression of ICAM-1 in K562 cells was detected by reverse transcriptase-polymerase chain reaction (RT-PCR). The results showed that the activity of NF-κB and the expression of ICAM-1 of K562 cells in each treatment group were significantly inhibited (P <0.05), and the activity of NF-κB in each group was similar to that of ICAM-1 -1 expression was positively correlated. CONCLUSION: Bortezomib, a proteasome inhibitor, may down-regulate ICAM-1 expression by inhibiting the activity of NF-κB, which provides a new approach for targeted therapy of leukemia.